Keoe (pronounced K-O-A) - executive strategic advisor partnering with private and public company management teams seeking a seasoned C-level executive in planning forward through business challenges, organizational scaling, corporate strategy and fundraising considerations.

Board MemberAudit CommitteeCompensation Committee

As President and CEO, Iead a dedicated team to bring forward therapeutics with the promise to make meaningful impact for patients. Ocelot Bio is a clinical-stage biopharmaceutical company focused on the development of innovative therapeutics designed to significantly improve outcomes for patients with complications associated with advanced liver disease. Our remote first approach to building our team will help us accelerate our company goals by finding the best talent for meeting those objectives - wherever they call home.

Chief Operating Officer for Graphite Bio a next-generation gene editing company pioneering a precision gene editing platform. Emerging from founding to IPO in less than 14 months, I joined as the second executive leader for the company and empowered to build the organization.In my first year as COO, oversaw the growth of the company from about a dozen employees to more than 50 across critical R&D and operational functions. To support Graphite Bio’s clinical development strategy and the progression of its pipeline of precision gene therapies, I also focused on implementing the capabilities and infrastructure that enable the company to be in a position to manufacture drug product for the early clinical study and enable new leaders to plan ahead for commercialization. As an operational leader at my core, I am thankful and proud to have been entrusted with helping guide and build Graphite Bio through the headwinds of COVID-19 and into the post-pandemic world as an agile, collaborative and patient-focused organization.

Embraced a new professional and personal adventure by accepting P&L accountability for Celgene’s operations in Spain and Portugal. Explored and seized opportunities to restructure, energize and accelerate the business across commercial, medical affairs, and market access functions. Within first 6 months, combined Spain and Portugal operations into a single region, ultimately growing the business and significantly improving operating margins in less than 2 years. Additionally, prepared local market for cellular therapy and was instrumental in defining the ecosystem for these novel treatment approaches.

Appointed to this franchise executive role after successfully steering the commercial and clinical transformation of a key asset. Built and integrated cross-functional development teams to optimize and enrich the portfolio—and accelerate global development. Influenced and directed a team of 30+ portfolio leaders and project managers. Strengthened governance and decision making by ensuring alignment in reporting project milestones, delivering consistency in IDPs, defining clear go/no go decisions at governance, and evolving uniform risk assessment across the portfolio.

Integrated Abraxis BioScience into the Celgene enterprise and followed through by revamping commercial strategy and growing the Abraxane® brand in the US market. As the opportunity expanded—and complexity deepened—I became the global project leader accountable for maximizing and accelerating a focused and aligned global clinical development plan expanding the global footprint across multiple indications in >50 countries and strengthening the evidence differentiating Abraxane with a robust life cycle effort.

Directed and enhanced Celgene’s patient assistance and reimbursement programs. Improved the patient experience—and upped accessibility—by advising commercial leadership and advocating for the “voice of the patient.” Created, championed, achieved buy-in, and implemented Celgene’s first commercial co-pay program.

Led pharmaceutical sales team to drive revenue for Revlimid® in five-state region. Contributed to integration efforts to build a single, collaborative organization following the acquisition of Pharmion Corporation.

Played integral role in establishing the European market from the ground up as Celgene’s first global product manager. Subsequently drove U.S. brand development for Revlimid® by launching the first myeloma indication, which generated >$500M revenue in first 12 months.

Contributed to Eli Lilly’s vision to reach patients around the world by serving in key positions: global brand development, strategic marketing, and market research. Focus in pipeline products and new indications across oncology, cardiovascular, and neuroscience therapeutic areas. Received multiple Lilly Marketing Excellence Awards.